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SUMMARY AND OUTCOMES
ApoE concentration in the CSF was significantly higher in PD patients.
Additional importance is that ApoE in the substantia nigra can also serve as a
biomarker. This suggests that ApoE is a reliable biomarker of PD.
ApoE increases alpha-synuclein spread and aggregation through high binding
affinity of alpha-synuclein for ApoE-containing vesicles. Though discrepancy
may exist, a majority view is consistent with the hypothesis that ApoE
contributes to the spread of alpha-synuclein in PD. More research will clarify
the issue of ApoE contribution to the spread of alpha-synuclein in the brain of
PD patients.
The present review suggests that ApoE level in CSF could serve as an earlier
and more accurate biomarker, and can be used as a target treatment prior to
onset of disease. Moreover, a target treatment which will lower levels of ApoE
could slow the spread of alpha-synuclein, leading to a slower onset of disease.
The present review also indicates that it is necessary to improve of the current
diagnostic criteria for ApoE based on symptoms before and after the onset of
neurodegenerative changes in Parkinson’s patients.
FUTURE STUDY
Larger sample size based on more research is needed focusing on ApoE and
interaction with alpha-synuclein in patients with PD.
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ABSTRACT
Parkinson’s disease (PD) is a common neurodegenerative disease that affects more than
10 million people worldwide. PD is a movement disorder, which causes tremor, rigidity,
bradykinesia, and postural instability. Although PD is characterized by degeneration of
dopamine neurons in the substantia nigra, the precise cause of degeneration or loss of
dopamine neurons is unknown. Studies suggest that specific gene mutations and
environmental factors may trigger PD. Other studies suggest that abnormal accumulation
of alpha-synuclein may cause degeneration of dopamine neurons, and that Lewy bodies
which contain alpha-synuclein are a histological hallmark of PD. Recent studies suggest
that high levels of Apolipoprotein E (ApoE) in the cerebrospinal fluid (CSF) may serve
as a biomarker of PD. ApoE is the most abundant protein for lipid transport in the brain
and a subtype, ApoE4, is also linked to Alzheimer’s disease. The present study reviewed
the reliability of ApoE as a biomarker of PD and the role of ApoE in accumulation of
alpha-synuclein. Hypothesis was two-folds: (1) ApoE level in the CSF is a reliable
biomarker of PD; (2) ApoE contributes to the spread of alpha-synuclein in PD.
Conclusion: Significantly high levels of ApoE in CSF and in the substantia nigra were
shown in PD patients (Gupta et al., 2019; Maarouf et al., 2012; Paslawski et al., 2019;
Rohn and Mack, 2018; Wilhemus et al., 2011). This suggests that ApoE in CSF can
serve as a reliable biomarker, and that ApoE in the substantia nigra as an additional
biomarker. In PD, ApoE increased alpha-synuclein aggregation through alpha-
synuclein’s high binding affinity for ApoE-containing vesicles (Gupta et al., 2019;
Emamzadeh et al., 2016; Paslawski et al., 2019). This suggests that ApoE contributes to
the spread of alpha-synuclein in PD. Further research is warranted.
BACKGROUND
Parkinson’s disease (PD) is a common neurodegenerative disease that affects more than
10 million people worldwide. The typical age of onset of PD is around age 60 or older.
Typical motor symptoms of PD are tremors, slowed movement, muscle rigidity, impaired
balance, and speech changes (Xia and Mao, 2012). PD also has cognitive symptoms such
as attention deficits, delay of mental processing, difficulties in problem solving or
executive function, impaired memory, psychosis, anxiety, and depression (Stacy, 2011).
The precise cause of degeneration and cell death in PD is unknown. However, there are
factors that appear to play a role such as specific gene mutations, such as mutations in the
SNCA gene which cause alpha-synuclein to misfold or be created in excess
(Polymeropoulos et al., 1997), in familial Parkinson’s disease, which counts for about 10
to 15 percent of cases. There are several environmental factors that have been found to
increase a person’s risk of developing Parkinson’s disease such as head trauma, exposure
to pesticides and environmental pollutants, and bacterial or viral infections (Johnson et
al., 2019) Parkinson’s disease develops as dopaminergic neurons of the substantia nigra
degenerate. The substantia nigra is part of the nigrostriatal pathway with is responsible
for movement, so its degeneration causes the motor symptoms of Parkinson’s disease.
The histological hallmark of Parkinson’s disease is Lewy bodies, which are abnormal
aggregations of protein in the brain. Aggregations of the protein alpha-synuclein are
found in all Lewy bodies. Two very important questions in Parkinson’s disease is how
alpha-synuclein spreads between cells and what are biomarkers that can be used for early
diagnosis.
Apolipoprotein E (ApoE) is the most abundant protein for lipid transport in the brain. Its
main function is to transport cholesterol (Emamzadeh et al., 2016). There are three alleles
of Apolipoprotein E, which are ApoE2, ApoE3, and ApoE4 (Emamzadeh, 2016). The
ApoE4 allele has been linked to an increased risk, and earlier onset, of Alzheimer’s
disease (Corder, 1993). Apolipoprotein E may also have a role in Parkinson’s disease.
Nevertheless, it is unclear whether or not ApoE level in cerebrospinal fluid (CSF) a
reliable biomarker and ApoE contribute to the spread of alpha-synuclein between
neurons in PD. Hypothesis was that ApoE level in the CSF would be a reliable
biomarker of PD; and that ApoE would contribute to the spread of alpha-synuclein
between neurons in PD.
METHODS
Review of empirical research about ApoE as a biomarker for PD and interaction between
ApoE and alpha-synuclein was used to test the hypotheses. Research evidence was
evaluated by the validity of outcomes and categorized by evidence that supports and does
not support the hypothesis, using a 2x2 design. The first factor is if ApoE is or is not a
reliable biomarker of PD. The second factor is if Apolipoprotein does or does not
contribute to the spread of alpha-synuclein in PD. Outcomes are organized in Table 1
and Table 2.
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RESULTS
TABLE 1: The research reviewed showed that ApoE concentration in the CFS and the substantia nigra is
significantly higher in PD patients, compared to controls. Moreover, ApoE is also present in Lewy bodies.
Although some studies had smaller sample sizes, increase in sample size will further clarify the reliability of
ApoE as a new biomarker in PD.
ApoE Level in the CSF as a Reliable Biomarker of PD
ApoE Contribution to the Spread of Alpha-Synuclein Between Neurons 
TABLE 2: The majority studies reviewed were in agreement with a positive correlation between high concentrations
of ApoE, especially ApoE4, and increased accumulation of alpha-synuclein in the brain and increased alpha-
synuclein pathology, leading to earlier onset of PD. Conversely, one study found an inverse relationship in that high
level of ApoE caused less accumulation of alpha-synuclein, which contradicts other reports with high levels of ApoE
in PD patients.
Supported by Research Not Supported Key Findings
Maarouf et al., Neurological 
Research, vol. 34, no. 7 (2012): 
669–676. 
In PD patients, ApoE level in CSF was significantly 
greater compared to controls. 
Post-mortem CSF
Paslawski et al., Proceedings of 
the National Academy of Sciences
vol. 116, no. 30 (2019): 5226-
5235. 
Increase of ApoE in CSF of PD patients
Small sample size 
Post-mortem brain tissue
Wilhemus et al., The American 
Journal of Pathology vol. 179, no. 
5 (2011): 152-156.
Increased level of ApoE in the substantia nigra of PD 
patients 
Maarouf et al., Neurological 
Research, vol. 34, no. 7 (2012): 
669–676. 
In PD patients, ApoE level in CSF was significantly 
greater compared to controls. 
Post-mortem CSF
Paslawski et al., Proceedings of 
the National Academy of Sciences
vol. 116, no. 30 (2019): 5226-
5235. 
Increase of ApoE in CSF of PD patients
Small sample size 
Post-mortem brain tissue
Wilhemus et al., The American 
Journal of Pathology vol. 179, no. 
5 (2011): 152-156.
Increased level of ApoE in the substantia nigra of PD 
patients 
Supported by Research Not Supported Key Findings
Buchanan et al., Neuroscience 
Letters vol. 411, no. 3 (2007): 
185-88.
Apolipoprotein E lowers age of onset of PD in women
Emamzadeh et al., Neuroscience 
Letters vol. 618 (2016): 146-51. 
ApoE4 increases the aggregation of alpha-synuclein more 
than other isoforms
Emamzadeh et al., 
Neuroscience Letters
vol. 618 (2016): 
146-51. 
Low level of ApoE=more aggregation and high level 
offer protection 
Gupta et al., Neuropsychiatric 
Disease and Treatment ,vol. 15 
(2019): 2073-085
Correlation between higher alpha-synuclein levels and 
higher ApoE levels. 
Paslawski et al., Proceedings of 
the National Academy of Sciences
vol. 116, no. 30 (2019): 5226-
5235. 
Alpha-synuclein attaches to ApoE vesicles 
Small sample size
Davis et al., Science 
Translational Medicine 12.529 
(2020). 1-14.
ApoE significantly increases alpha-synuclein 
accumulation
Zhoa et al., Alzheimer's & 
Dementia 15 (2019): 1-15.
ApoE4 significantly increases alpha-synuclein pathology 
in substantia nigra in PD
Post-mortem brain tissue and animal model
